Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0704 • ACR Convergence 2022
Clinically Suspect Arthralgia Patients with a Low Educational Attainment Have an Increased Risk to Develop Inflammatory Arthritis
Sarah J.H. Khidir¹, Anna M.P. Boeren², Annelies Boonen³, Pascal de Jong⁴, Elise van Mulligen⁵ and Annette van der Helm-van Mil⁶, ¹Leiden University Medical Center, Leiden, Netherlands, ²Erasmus MC, Rotterdam, Rotterdam, ³Maastricht University Medical Centre, Maastricht, Netherlands, ⁴ErasmusMC, Hendrik Ido Ambacht, Netherlands, ⁵Erasmus Medical Center, Leiden University Medical Center, Rotterdam, Netherlands, ⁶Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Cross-sectional studies have shown that rheumatoid arthritis (RA) is more prevalent among people with a lower educational attainment. To date, no longitudinal data are…
Abstract Number: 0765 • ACR Convergence 2022
The Impact of Immunomodulating Treatment on the Immunogenicity of COVID-19 Vaccines in Patients with Immune-mediated Inflammatory Rheumatic Diseases Compared to Healthy Controls. a Swedish Nationwide Study (COVID19-REUMA)
Martina Frodlund¹, Katerina Chatzidionysiou², Anna Södergren³, Eva Klingberg⁴, Anders A Bengtsson⁵, Monika Hansson², Sophie Ohlsson⁶, Elisa Pin⁷, Lars Klareskog⁸ and Meliha Kapetanovic⁹, ¹Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ²Department of Medicine, Solna, Division of Rheumatology, Karolinska University Hospital at Karolinska Institutet, Stockholm, Sweden, ³Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden and Wallenberg Centre for Molecular Medicine (WCMM), Umeå University, Umeå, Sweden, ⁴Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁵Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, ⁶Department of Clinical Sciences, Lund, Section for Nephrology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, ⁷Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden, ⁸Karolinska Institutet, Stockholm, Sweden, ⁹Lund University, Department for clinical sciences Lund, section of rheumatology and Lund University Hospital Lund and Malmö, Lund, Sweden
Background/Purpose: The aim of the study was to elucidate antibody responses after vaccination with two doses of COVID-19 vaccines in patients with inflammatory rheumatic diseases…
Abstract Number: 0885 • ACR Convergence 2022
Association Between Changes in Inflammatory Pathways Associated with a Reduction in CV Risk: Results from the LiiRA Study
brittany weber¹, Dana Weisenfeld¹, Thany Seyok¹, Elena Massarotti¹, Selena Huang¹, Derrick Todd¹, Jonathan Coblyn¹, michael weinblatt¹, Tianrun Cai¹, Kumar Dahal¹, leanne BArrett¹, Daniel Solomon¹, Jorge Plutzky¹, Marcy Bolster², marcelo Dicarli¹ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased cardiovascular (CV) risk. Coronary flow reserve (CFR) is a quantitative imaging biomarker of CV risk that…
Abstract Number: 0901 • ACR Convergence 2022
Factors Associated with Household Work Limitations in Mexican Patients with Rheumatoid Arthritis: The Impact of the Disease on Women’s Life
Ana Ortiz-Haro¹, Irazu Contreras-Yáñez¹, Guillermo Guaracha Basañez² and Virginia Pascual Ramos³, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirn", Ciudad de México, Mexico, ³Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Mexico
Background/Purpose: Rheumatoid arthritis (RA) is the most frequent chronic inflammatory arthritis with a clear female preponderance. For various reasons, women spend more time on household…
Abstract Number: 0917 • ACR Convergence 2022
Fifty-two-week Results from a Phase 3, Randomized, Double-blind, Active-controlled Clinical Trial to Compare BAT1806/BIIB800, a Proposed Tocilizumab Biosimilar, with a Tocilizumab Reference Product in Subjects with Moderate to Severe RA with an Inadequate Response to Methotrexate
Xiaomei Leng¹, Piotr Leszczynski², Sławomir Jeka³, Shengyun Liu⁴, Huaxiang Liu⁵, Malgorzata Miakisz⁶, Jieruo Gu⁷, Lali Kilasonia⁸, Mykola Stanislavchuk⁹, Xiaolei Yang¹⁰, Yinbo Zhou¹¹, Qingfeng Dong¹¹, Marian Mitroiu¹², Janet Addison¹³ and Xiaofeng Zeng¹⁴, ¹Peking Union Medical College Hospital, Department of Rheumatology and Clinical Immunology, Beijing, China, ²Poznan University of Medical Sciences, Department of Rheumatology, Rehabilitation and Internal Medicine, Poznan, Poland, ³University Hospital No 2 in Bydgoszcz Collegium Medicum UMK, Clinic and Department of Rheumatology and Connective Tissue Diseases, Bydgoszcz, Poland, ⁴First Affiliated Hospital of Zhengzhou University, Department of Rheumatology and Immunology, Zhengzhou, China, ⁵Qilu Hospital of Shandong University, Department of Rheumatology, Jinan, China, ⁶Twoja Przychodnia Centrum Medyczne, Internal Medicine and Rheumatology, Nowa Sól, Poland, ⁷The Third Affiliated Hospital of Sun Yat-sen University, Department of Rheumatology, Guangzhou, China, ⁸Tbilisi Heart and Vascular Clinic Ltd, Rheumatology, Tbilisi, Georgia, ⁹National Pirogov Memorial Medical University, Internal Medicine, Vinnytsia, Ukraine, ¹⁰Bio-Thera Solutions, Ltd., Research and Development, Guangzhou, China, ¹¹Bio-Thera Solutions Ltd, Research and Development, Guangzhou, China, ¹²Biogen International GmbH, Evidence Generation Biosimilars, Baar, Switzerland, ¹³Biogen Idec Ltd, Maidenhead, United Kingdom, ¹⁴Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: BAT1806 (also referred to as BIIB800) is a proposed biosimilar to tocilizumab reference product (TCZ). Results of this Phase 3, randomized, double-blind, active-controlled trial…
Abstract Number: 0934 • ACR Convergence 2022
Impact of Tapering Targeted Therapy on Disease Activity Is Different Based on Concomitant Methotrexate Use in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study
Jun Won Park¹, Min Jung Kim², Hyoun-Ah Kim³, Jinhyun Kim⁴, Eun Bong Lee¹ and Kichul Shin⁵, ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, Republic of Korea, ³Ajou University School of Medicine, Suwon, Republic of Korea, ⁴Chungnam National University Hospital, Jung-gu, Daejeon, South Korea, ⁵Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea
Background/Purpose: The American College of Rheumatology and the European League Against Rheumatism recommend using methotrexate (MTX) with targeted therapy. Previous studies have shown that tapering…
Abstract Number: 1137 • ACR Convergence 2022
MHC Class I Polypeptide-Related Sequence a Variant Predicts Real-World Response to Anti-TNF Therapy
Kristin Wipfler¹, Joshua Baker² and Kaleb Michaud³, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: MHC class I polypeptide-related sequence A (MICA) is a protein involved in the activation of NK and T cells. Variants within the MICA gene…
Abstract Number: 1252 • ACR Convergence 2022
Interrater Agreement of Hand Ultrasounds in Inflammatory Arthritis
Annie H Yang¹, Norman Madsen², Bethany Marston¹, Brian H. Nathanson³, Darren Tabechian⁴ and Allen Anandarajah⁵, ¹University of Rochester, Rochester, NY, ²University of Rochester, NY, Rochester, NY, ³OptiStatim, LLC, Longmeadow, MA, ⁴URMC, Rochester, NY, ⁵University of Rochester, Rochester
Background/Purpose: Musculoskeletal ultrasound (US) is an imaging modality that is more sensitive in identifying synovitis due to inflammatory arthritis than clinical examination. Little is known…
Abstract Number: 1354 • ACR Convergence 2022
Early Real-World Effectiveness of Upadacitinib in Rheumatoid Arthritis Using Patient-Reported Outcomes Collected via Mobile Application
Leslie Harrold¹, Patrick Zueger², William Benjamin Nowell³, Taylor Blachley¹, Paul Lakin¹, David Curtis⁴, Laura Stradford³, Shilpa Venkatachalam⁵, Namita Tundia² and Pankaj Patel², ¹CorEvitas, LLC, Waltham, MA, ²AbbVie, Inc., North Chicago, IL, ³Global Healthy Living Foundation, Nyack, NY, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵Global Healthy Living Foundation, New York, NY
Background/Purpose: Little is known about the impact of upadacitinib (UPA) in rheumatoid arthritis (RA) during the initial weeks of therapy in real-world clinical practice. Our…
Abstract Number: 1401 • ACR Convergence 2022
Relationship Between Disease Activity and Adverse Events of Interest in Patients with RA on Tofacitinib or TNF Inhibitors: Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study
George A Karpouzas¹, Zoltan Szekanecz², Eva Baecklund³, Ted Mikuls⁴, Deepak L Bhatt⁵, Harry Shi⁶, Cunshan Wang⁷, Gosford A Sawyerr⁸, Yan Chen⁶, Sujatha Menon⁷, Carol A Connell⁷, Steven R Ytterberg⁹ and Mahta Mortezavi⁸, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Division of Rheumatology, Faculty of Medicine, Debrecen, Hungary, ³Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁴Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵Department of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁶Pfizer, Inc, Collegeville, PA, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, New York, NY, ⁹Division of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Uncontrolled RA activity and acute disease flares are associated with higher risk of adverse outcomes, such as cardiovascular (CV) disease, venous thromboembolism (VTE), malignancy,…
Abstract Number: 1417 • ACR Convergence 2022
Clinical and Demographic Characteristics of Patients with RF+/ACPA+ RA and First-Line TNF Inhibitor versus Abatacept Treatment Choice in Real-World Clinical Practice
Gordon Lam¹, Hanke Zheng², Emily Bland³, Vardhaman Patel⁴, Laetitia N’Dri⁵, Parisa Asgarisabet³, Keith Wittstock⁴, Cherrishe Brown-Bickerstaff³, Mark Chaballa², Bruce Feinberg³, Vadim Khaychuk⁶ and Andrew J Klink³, ¹Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²Bristol Myers Squibb, Princeton, NJ, ³Cardinal Health, Dublin, OH, ⁴Bristol Myers Squibb, Lawrence Township, NJ, ⁵Bristol Myers Squibb, Princeton, ⁶Bristol Myers Squibb, Pennington, MA
Background/Purpose: Early intensive treatment (tx) is an accepted paradigm in the tx of patients (pts) with RA with poor prognostic factors (eg, RF/ACPA seropositivity); however,…
Abstract Number: 1438 • ACR Convergence 2022
The Ratio Between Biological and Glucocorticoid Use in Different Countries Worldwide: Results from the METEOR Registry
Isabell Nevins¹, CF Allaart¹, David Vega Morales², Lai Ling Winchow³, Arvind Chopra⁴, Ana Maria Rodrigues⁵, Tom Huizinga¹, Maarten Boers⁶ and Sytske Anne Bergstra⁷, ¹Leiden University Medical Center, Leiden, Netherlands, ²Autonomous University of Nuevo León, Monterrey, Mexico, ³Chris hani baragwanath academic hospital, Johannesburg, South Africa, ⁴Center for Rheumatic Diseases, Pune, Maharashtra, India, ⁵Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal, ⁶Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁷LUMC, Leiden, Netherlands
Background/Purpose: Previous studies have demonstrated differing bDMARD prescription rates between countries, which seems to be amongst others related to a country's socioeconomic status. In contrast,…
Abstract Number: 1638 • ACR Convergence 2022
Epidemiology of Rheumatoid Arthritis and Rheumatoid Arthritis-Interstitial Lung Disease in the Veterans Health Administration from 2004 to 2018
Benjamin Fletcher¹, Punyasha Roul², Yangyuna Yang³, Brian Sauer⁴, Jorge Rojas⁵, Grant Cannon⁶, Joshua Baker⁷, Ted Mikuls⁸ and Bryant England³, ¹University of Nebraska Medical Center, Omaha, ²UNMC, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁵George E. Wahlen Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ⁶Salt Lake City VA, Salt Lake city, ⁷University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ⁸Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Epidemiologic studies estimating RA prevalence and incidence have primarily been conducted in populations where the majority of RA patients are women. Because of phenotypic…
Abstract Number: 1739 • ACR Convergence 2022
Single-Cell Characterization of the TCR Repertoire Across Tissue and Blood in Rheumatoid Arthritis
Garrett Dunlap¹, Aaron Wagner², Nida Meednu³, Anna Jonsson⁴, Fan Zhang⁵, Kevin Wei⁶, Paul Utz⁷, William Robinson⁷, Holden Maecker⁷, Judith James⁸, Joel Guthridge⁸, S. Louis Bridges, Jr.⁹, Laura Donlin⁹, Susan Goodman⁹, Edward DiCarlo⁹, Vivian Bykerk⁹, Christopher Ritchlin¹⁰, Darren Tabechian¹¹, James Lederer⁴, Ellen Gravallese¹², Mandy McGeachy¹³, Gary S. Firestein¹⁴, Peter Gregersen¹⁵, Diane Horowitz¹⁶, David Boyle¹⁷, Laura Geraldino-Pardilla¹⁸, Harris Perlman¹⁹, Arthur Mandelin²⁰, Joan Bathon¹⁸, Laura Hughes²¹, V. Michael Holers²², Kevin D Deane²³, Larry Moreland²², Andrew Filer²⁴, Costantino Pitzalis²⁵, Lindsy Forbess²⁶, Ami Ben-artzi²⁷, Karen Salomon-Escoto²⁸, Soumya Raychaudhuri⁴, Michael Brenner¹², Accelerating Medicines Partership (AMP) RA/SLE Network²⁹, Andrew McDavid², Jennifer Anolik³ and Deepak Rao⁴, ¹Harvard University, Boston, MA, ²University of Rochester, Rochester, NY, ³University of Rochester Medical center, Rochester, NY, ⁴Brigham and Women's Hospital, Boston, MA, ⁵University of Colorado, Aurora, CO, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Stanford University School of Medicine, Palo Alto, CA, ⁸Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Hospital for Special Surgery, New York, NY, ¹⁰Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ¹¹URMC, Rochester, NY, ¹²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹³University of Pittsburgh, Pittsburgh, PA, ¹⁴University of California, San Diego, San Diego, CA, ¹⁵The Feinstein Inst for Med Research, Larchmont, NY, ¹⁶Northwell Health, Jericho, NY, ¹⁷UCSD, La Jolla, CA, ¹⁸Columbia University, New York, NY, ¹⁹Northwestern University, Chicago, IL, ²⁰Northwestern University Feinberg School of Medicine, Chicago, IL, ²¹University of Alabama at Birmingham, Birmingham, AL, ²²University of Colorado, Denver, CO, ²³University of Colorado Denver Anschutz Medical Campus, Denver, CO, ²⁴University of Birmingham, Birmingham, United Kingdom, ²⁵Queen Mary University of London, London, United Kingdom, ²⁶Cedars-Sinai Medical Center, Los Angeles, CA, ²⁷Ami Ben-Artzi, MD Inc., Beverly Hills, CA, ²⁸University of Massachusetts Medical School, Worcester, MA, ²⁹National Institutes of Health, Washington, DC
Background/Purpose: In rheumatoid arthritis (RA), T cells represent a large proportion of the immune population present in inflamed joint synovium, and subsets of both CD4+…
Abstract Number: 1771 • ACR Convergence 2022
The Effectiveness of a Treat-to-target Strategy in Rheumatic Diseases: A Systematic Literature Review and Meta-analysis
Yanjie Hao¹, Shereen Oon² and Mandana Nikpour³, ¹The University of Melbourne, Melbourne, Australia, ²The University of Melbourne Department of Medicine at St. Vincent’s Hospital Melbourne, Melbourne, Australia, ³The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia
Background/Purpose: The concept of treat-to-target (T2T), a strategy in which treatment is directed to reach and maintain a defined goal such as remission or low…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].